Should Parents of Children With Severe Disabilities Be Allowed to Stop Their Growth?
By Genevieve Field,
The New York Times Magazine
| 03. 22. 2016
Untitled Document
Ricky gazed up toward the pine trees as his mother, Cindy Preslar, pushed him along the village road in an orange jogging stroller. She was marking the route for the Summer 2014 Run Through the Clouds 10K, a fund-raiser for the public schools in Cloudcroft, N.M. “You’ll run with Dad and Max tomorrow,” she said. “Right, Ricky?” She ruffled his fine blond hair. By “run” she meant “ride” — Ricky was 7, but his legs were unable to bear his full weight. As a result of a complication during pregnancy, Cindy says, he was born with a form of cerebral palsy known as spastic quadriplegia with static encephalopathy, which meant permanent brain damage and severely limited eyesight because of cortical vision impairment.
Ricky’s problems were not recognized immediately. He was a fussy eater but an otherwise genial baby; the Preslars’ friends commented on the twinkle in his eyes. Then, at about 3 months, he began to jolt awake at night, the back of his pajamas soaked with sweat. One afternoon, when Cindy laid him on his changing table...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...